Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Research Abstract |
This study examined the availability of a novel drug in the treatment of myasthenia gravis with antibodies against muscle-specific kinase (MuSK-MG) using experimental animal model. The results provided the evidence that only low-dose cholinesterase inhibitors should be used to avoid side effect, and that 3,4-diaminopyridine will be effective as a mainstay in the symptomatic therapy of MuSK-MG.
|